

ARGUS IRB

ARGUS INDEPENDENT REVIEW BOARD
 6668 S. HIDDEN FLOWER WAY • TUCSON, AZ 85756
 (520) 298-7494 • FAX (520) 298-7494
 www.argusirb.com • argusirb@gmail.com

STUDY STATUS REPORT FORM

General Information	
Protocol Number:	
Sponsor:	
Principal Investigator:	
Site Contact for this Study:	
Phone:	
Fax:	

I certify that I have thoroughly reviewed the information provided on this report form.
 I also certify that the information provided in response to the questions of Argus is true and accurate.

 Signature of Principal Investigator (**Required**) _____
 Date (mm/dd/yy)

1. Submit consent documents.

You must submit a copy of the most recent version of the informed consent document (ICD), addendum consent document, and sub-study consent document *signed and dated by the most recently consented subject.*

2. What TYPE of report are you submitting?

- Interim
 Continuing Review (when applying for **re-approval** of the study at your site)
 Final

(a) Provide date of final contact with the last study subject: _____(mm/dd/yy)
(b) Are any subjects still participating in this study, including follow-up or subjects being followed until death for survival analysis? Yes No
NOTE: If any subjects are currently being followed, this cannot be a final report until all follow-up is completed.

3. Is enrollment OPEN at your site? Yes No

4. What was the DATE the 1st (first) subject was consented at your site? _____(mm/dd/yy)

5. Calculate how many subjects are still ACTIVE in the study.

Subjects	Initial Study	Study Extension 1	Study Extension 2
		IRB#:	IRB#:
(a) # Consented			
(b) # Screen Failures			
(c) # <i>Dropped*</i> (see note)			
(d) # Completed Study			
(e) # Still Active in Study			

Please calculate ACTIVE subjects: (e) = (a) – (b) – (c) – (d)

***NOTE:** List the specific reason for each dropped or withdrawn subject since your last submitted report.
 Please use subject initials or numbers when listing each specific reason.

Reasons: _____

6. List the number of CONSENTED subjects in each category below:

Gender:	# Male	# Female
Ethnicity:	# Hispanic	# Non-Hispanic
Race:	# Caucasian	# African-American
	# Asian-American	# Native American <input type="text"/> # Other

ARGUS IRB

ARGUS INDEPENDENT REVIEW BOARD
6668 S. HIDDEN FLOWER WAY • TUCSON, AZ 85756
(520) 298-7494 • FAX (520) 298-7494
www.argusirb.com • argusirb@gmail.com

7. Indicate whether any of the following have occurred at your site since your last report:

- | | | |
|---|------------------------------|-----------------------------|
| (a) Advertisements / Recruiting Materials | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (b) Significant Protocol Deviations | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (c) Protocol Amendments | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (d) Change of Site Location | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (e) Change of Principal Investigator | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (f) Change of Sub-Investigator | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (g) Change in Compensation | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| (h) Serious Adverse Events (SAEs) | <input type="checkbox"/> Yes | <input type="checkbox"/> No |

→ If Yes, how many SAEs have occurred?

of SAEs:

→ SAEs must be reported to Argus **within 3 business days** of the site becoming aware of the SAE.

8. Since your last report, have there been any unanticipated problems involving risk to subjects or others (such as breach of confidentiality or increased cost to the subject)? Yes No

9. Since your last report, have you provided your subjects with any additional information not contained in an SAIRB approved document that may affect their willingness to stay in the study? Yes No

10. Since your last report, has an IRB terminated, suspended, imposed restrictions or sanctions upon research at your site, or refused to review a protocol for any investigator associated with this study? Yes No

11. Since your last report, have any subjects at this site sought compensation for injury or made complaints regarding the conduct of the study? Yes No

12. Since your last report, has anything occurred in this study, which, in your opinion, would alter the initial risk/benefit analysis of this study? Yes No

13. Since your last report, has a state medical board taken disciplinary action against any investigator associated with this study? Yes No

14. Are there state medical board complaints and/or charges currently pending against any investigator associated with this study? Yes No

NOTE: If you answered **Yes** to any questions numbered **#8** through **#14**, you must provide a detailed explanation and submit any pertinent documentation.

15. Has your site been **AUDITED** during this study? Yes No
(a) If Yes, by what entity? FDA IRB

(b) What was the date of the audit? _____(mm/dd/yy)

(c) Name of the physician/investigator who was the subject of the audit:

(d) Copy of audit report or findings attached:

Yes Previously Submitted Will submit when available

16. Since your last report, have you consented subjects from the following **VULNERABLE** groups? Yes No

If **Yes**, check ALL that apply:

- | | |
|--|--|
| <input type="checkbox"/> Children (anyone under the age of majority in your state) | <input type="checkbox"/> Consented via legally authorized representative |
| <input type="checkbox"/> Anyone who cannot read (blind or illiterate subjects) | <input type="checkbox"/> Non-English speaking persons |
| <input type="checkbox"/> Employees/immediate family members of employees | |

NOTE: Submit one signed and dated copy of the **informed consent** document (and child's assent, if applicable) from each marked category by the most recently consented subject.